Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that its board of directors has initiated a strategic review to evaluate potential business opportunities within the broader health and wellness sector. As part of this review, the Company's board of directors and senior management are examining a range of potential strategic initiatives, which may include prospective b
Produits ménagers / de consommation / cosmétiques, Psychédéliques
2026-05-01 2:40 PM EDT | Adaptogenics Health Corp.
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.
Steep Hill Announces Debt Settlement
Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") announces that it intends to settle an aggregate of $79,278.00 of indebtedness to a non-arm's length creditors of the Company through the issuance of 1,321,300 common shares in the capital of the Company (the "Common Shares") at a price of $0.06 per Common Share (the "Debt Settlement"). The Common Shares issued pursuant to the Debt Settlement
Commerce de détail, Cannabis, Psychédéliques, Producteurs de cannabis
2026-04-30 4:00 PM EDT | Steep Hill Inc.
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities Positions the Company at the forefront of the rapidly emerging regu
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-30 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Ligh
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-29 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") hel
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-27 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions. Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-24 8:26 AM EDT | Red Light Holland Corp.
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company. Recent announcements by U.S. President Donald Trump include an exec
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-04-23 7:30 AM EDT | Psyched Wellness Ltd.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Numinus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD. The Order directs the FDA to prioritize review of psychedelics with Breakthrough Therapy designation, establishes new investigational acces
2026-04-20 8:30 AM EDT | Numinus Wellness Inc.
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks 69% of participants fell below clinical thresholds for anxiety and depression after second treatment Research builds on prior studies utilizing Filament's botanica
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-20 7:30 AM EDT | Red Light Holland Corp.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global cl
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-07 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate us
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-01 9:20 AM EDT | Red Light Holland Corp.
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
Numinus Wellness Provides Update Regarding Listing Status
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX"). As previously disclosed in the Company's management information circular dated July 29,
2026-03-24 5:00 PM EDT | Numinus Wellness Inc.
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstandin
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-23 8:15 AM EDT | Red Light Holland Corp.
Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director
Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces the closing of (i) the first tranche of its non-brokered private placement (the "Offering") for gross proceeds of C$859,653.47, led by Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together with the
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-03-20 9:16 AM EDT | Psyched Wellness Ltd.
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Li
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-18 8:15 AM EDT | Red Light Holland Corp.